In the late 90s, during my PhD, I was struggling with just 30 SSR markers while developing a library of introgression lines in Arabidopsis thaliana. In 2000, the full genome of this model plant was published\u2014after 10 years of work, involving over 300 researchers across six countries, and a budget of around $80 million.
Fast forward 25 years: the landscape of plant genomics has been revolutionized.
\ud83d\ude80 Today, we are witnessing the democratisation of molecular breeding\u2014what once required massive public investment and elite research institutions is now accessible to small and medium-sized seed companies.
Here\u2019s what\u2019s changed:
1\ufe0f\u20e3 Hundreds of plant genomes have been sequenced and are publicly available.
2\ufe0f\u20e3 Molecular markers linked to major QTLs and causal mutations are known for many key traits.
3\ufe0f\u20e3 Portable, modular, and low-cost genotyping instruments are commercially available.
4\ufe0f\u20e3 Cloud-based computing and digital breeding tools are within reach for most users.
5\ufe0f\u20e3 Many plant breeders now have training in molecular genetics or collaborate with those who do.
All of this means that small and mid-sized breeding programs can now build in-house molecular capacity\u2014and do so with a realistic and fast return on investment.
\ud835\udde3\ud835\uddff\ud835\uddee\ud835\uddf0\ud835\ude01\ud835\uddf6\ud835\uddf0\ud835\uddee\ud835\uddf9 \ud835\uddd6\ud835\uddf5\ud835\uddf2\ud835\uddf0\ud835\uddf8\ud835\uddf9\ud835\uddf6\ud835\ude00\ud835\ude01: \ud835\udddc\ud835\ude00 \ud835\ude01\ud835\uddf5\ud835\uddf2 \ud835\uddd6\ud835\uddfc\ud835\uddfa\ud835\uddfd\ud835\uddee\ud835\uddfb\ud835\ude06 \ud835\udde5\ud835\uddf2\ud835\uddee\ud835\uddf1\ud835\ude06 \ud835\uddf3\ud835\uddfc\ud835\uddff \ud835\udddc\ud835\uddfb-\ud835\udddb\ud835\uddfc\ud835\ude02\ud835\ude00\ud835\uddf2 \ud835\uddda\ud835\uddf2\ud835\uddfb\ud835\uddfc\ud835\ude01\ud835\ude06\ud835\uddfd\ud835\uddf6\ud835\uddfb\ud835\uddf4?
\ud83d\udd38Does the company handle hundreds or thousands of samples per season?
\ud83d\udd38Are molecular markers already being used for selection, purity testing, or backcrossing?
\ud83d\udd38Is there a need for faster\u00a0 result turnaround than external labs can offer (e.g., 3\u20137 days instead of weeks)?
\ud83d\udd38Does the team include staff trained in DNA extraction and genotyping workflows?
\ud83d\udd38Is keeping proprietary markers and data confidential a priority?
\ud83d\udd38Is there access to validated markers for traits of interest\u2014or the capacity to develop them?
\ud83d\udd38Is there a budget for setup (\u20ac30K\u2013\u20ac200K) and ongoing operational costs?
\ud83d\udd38Is there a dedicated lab space with basic infrastructure (power, temperature control, storage)?
\ud83d\udd38Is the company looking to reduce long-term outsourcing costs and gain technical independence?
\ud83d\udc49 If you checked most of the boxes above, it’s time to run the numbers. \ud835\udde8\ud835\ude00\ud835\uddf2 \ud835\uddee\ud835\uddfb \ud835\udde5\ud835\udde2\ud835\udddc (\ud835\udde5\ud835\uddf2\ud835\ude01\ud835\ude02\ud835\uddff\ud835\uddfb \ud835\uddfc\ud835\uddfb \ud835\udddc\ud835\uddfb\ud835\ude03\ud835\uddf2\ud835\ude00\ud835\ude01\ud835\uddfa\ud835\uddf2\ud835\uddfb\ud835\ude01) calculator to assess whether building an in-house genotyping facility makes financial sense for your company. ROI is a tool that helps you evaluate the financial return on an investment compared to its cost. It can show you how quickly your investment could pay for itself and help you understand the long-term benefits.
The tools are no longer the barrier \u2014 it’s all about vision, planning, and strategic investment. \ud83d\ude80<\/p>\n